New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus
Benjamín Diethelm-Varela,Jorge A Soto,Claudia A Riedel,Susan M Bueno,Alexis M Kalergis
DOI: https://doi.org/10.2147/IDR.S379660
2023-04-08
Infection and Drug Resistance
Abstract:Benjamín Diethelm-Varela, 1 Jorge A Soto, 1, 2 Claudia A Riedel, 2 Susan M Bueno, 1 Alexis M Kalergis 1, 3 1 Millennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile; 2 Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile; 3 Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile Correspondence: Alexis M Kalergis, Email Since the discovery of the human respiratory syncytial virus (hRSV), multiple research efforts have been conducted to develop vaccines and treatments capable of reducing the risk of severe disease, hospitalization, long-term sequelae, and death from this pathogen in susceptible populations. In this sense, therapies specifically directed against hRSV are mainly based on monoclonal and polyclonal antibodies such as intravenous IgG (IVIG)-RSV and the monoclonal antibody palivizumab. However, these therapies are associated with significant limitations, including the need for the recruitment of a high number of convalescent volunteers who donate blood to procure IVIG-RSV and the costs associated with the need for repeated administrations of palivizumab. These limitations render this product not cost-effective for populations other than high-risk patients. These problems have underscored that it is still necessary to identify new safe and effective therapies for human use. However, these new therapies must benefit from a comparatively cheap production cost and the opportunity to be available to the high-risk population and anyone who requires treatment. Here, we review the different antibodies used to prevent the pathology caused by hRSV infection, highlighting therapies currently approved for human use and their clinical value. Also, the new, most promising candidates based on preclinical studies and clinical trial results are revised. Keywords: prevention, treatment, antibodies, respiratory syncytial virus The human respiratory syncytial virus (hRSV) or human orthopneumovirus, based on its reclassification in 2016, 1,2 is a pathogen of primary global concern. 3–8 This infectious agent is responsible for seasonal outbreaks associated with significant morbidity and mortality. 3,5,7,9,10 High-risk populations for severe outcomes following hRSV infections consist of preterm children, especially those with biomedical complications such as bronchopulmonary dysplasia, 11 as well as the elderly. 3,7,10,12–15 In these high-risk populations, hRSV infection has a significantly higher likelihood of causing lower respiratory tract disease, leading to life-threatening pneumonia in many cases. 16,17 Nevertheless, it is important to note that healthy infants born at term are also at risk for severe hRSV pneumonia (albeit to a lesser degree than preterm infants), and due to the ubiquity of the virus, make up most cases. 4,12,13,18 Additionally, substantial evidence has emerged that infection with this virus, including infections acquired during infancy, is associated with long-lasting chronic sequelae, including neuropsychiatric alterations, 19–24 asthma, airway dysfunction, and susceptibility to allergies. These latter three consequences are associated with the highly inflammatory immune response that hRSV elicits. Therefore, it is a public health priority to prevent the severe health consequences brought by the immunopathology of hRSV infection, particularly in at-risk populations, either through active immunization, immunoprophylaxis, or early treatment. 21,22,25 No vaccines against hRSV have been approved. 25–28 Furthermore, only a single prophylactic antibody product, palivizumab, is licensed in a limited selection of cases. 17,29,30 In this sense, in most cases of hRSV infection, the primary management strategies are prevention, symptomatic management, and supportive therapy. 31 To understand the lack of vaccines against hRSV, the immune response that the organism mounts against this virus during infancy offers critical insights. During early life, the immune response tends to be polarized toward a Th2 profile. 32,33 Thus, upon infection, hRSV promotes infants to develop an allergy-like Th2-biased immune response. 34,35 This response includes considerable lung and airway inflammation, and the establishment of ineffective immune memory leaves the individual susceptible to future reinfections. 8,18,36 A vaccine candidate once seen as promising, consis -Abstract Truncated-
pharmacology & pharmacy,infectious diseases